Innovestor Life Science Fund and Tesi led the financing round. HVR Cardio declined to disclose its planned use(s) for the proceeds.
Helsinki, Finland-based HVR Cardio develops transcatheter mitral valve repair (TMVR) solutions based on its proprietary helix technology. Its CathHelix device remains investigational in all geographies.
“MR is a common valvular heart disease impacting millions of people and leaving a significant need for better treatment options,” said Pekka Simula, Innovestor partner. We are truly excited about the elegant and minimally invasive CathHelix technology that will offer new hope for patients.”
HVR Cardio also announced a new leadership team to accompany the financing round.
Tom Fleming joined the company as CEO in May 2022. He brings with him 21 years o…